83.21
-1.00 (-1.19%)
| Previous Close | 84.21 |
| Open | 84.21 |
| Volume | 1,146,513 |
| Avg. Volume (3M) | 1,062,468 |
| Market Cap | 13,100,332,032 |
| Price / Earnings (TTM) | 49.53 |
| Price / Earnings (Forward) | 32.79 |
| Price / Sales | 8.50 |
| Price / Book | 5.17 |
| 52 Weeks Range | |
| Earnings Date | 2 Aug 2023 - 7 Aug 2023 |
| TTM Dividend Yield | 0.55% |
| Profit Margin | 10.89% |
| Operating Margin (TTM) | 14.10% |
| Diluted EPS (TTM) | 0.830 |
| Quarterly Revenue Growth (YOY) | 4.20% |
| Quarterly Earnings Growth (YOY) | -54.00% |
| Total Debt/Equity (MRQ) | 20.99% |
| Current Ratio (MRQ) | 3.71 |
| Operating Cash Flow (TTM) | 264.85 M |
| Levered Free Cash Flow (TTM) | 244.41 M |
| Return on Assets (TTM) | 5.23% |
| Return on Equity (TTM) | 6.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Bio-Techne Corp | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -2.13 |
|
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 1.07% |
| % Held by Institutions | 106.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (TD Cowen, -3.86%) | Buy |
| Median | 69.00 (-17.08%) | |
| Low | 65.00 (Stifel, -21.88%) | Hold |
| Average | 71.67 (-13.87%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 62.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 05 Feb 2026 | 68.00 (-18.28%) | Hold | 63.92 |
| 05 Jan 2026 | 62.00 (-25.49%) | Hold | 63.03 | |
| Stifel | 05 Feb 2026 | 65.00 (-21.88%) | Hold | 63.92 |
| TD Cowen | 05 Feb 2026 | 80.00 (-3.86%) | Buy | 63.92 |
| UBS | 05 Feb 2026 | 79.00 (-5.06%) | Buy | 63.92 |
| 06 Nov 2025 | 70.00 (-15.88%) | Buy | 58.18 | |
| Argus Research | 20 Nov 2025 | 68.00 (-18.28%) | Buy | 58.73 |
| Wells Fargo | 06 Nov 2025 | 70.00 (-15.88%) | Buy | 58.18 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |